|
Objective: To investigate the P-glycoprotein (P-glycoprotein, P-gp), glutathione S-transferase-π (Glutathione-transferase pi, GST-π) and DNA topoisomerase Ⅱ (Topoisomerase Ⅱ, Topo Ⅱ) expression in cervical carcinoma and its clinical significance. Methods: Immunohistochemical EnVision method detected 20 cases of normal cervical 60 previously untreated patients with cervical cancer and 10 patients with recurrent cervical carcinoma, 30 cases of cervical intraepithelial neoplasia (cervical intraepithelial neoplasm, CIN), P-gp, GST-π Topo II expression, analysis of the relationship between P-gp, GST-π expression of Topo Ⅱ cervical cancer patients with clinical and pathological features and 3-year survival. Results: (1) P-gp, GST-π, Topo Ⅱ expression in normal cervix, CIN, the initial treatment of cervical cancer and recurrent cervical cancer tissue: normal cervix, CIN, the initial treatment of cervical cancer and recurrence of cervical cancer tissue P- gp was positive expression rate was 25%, 63%, 85% and 100%, GST-π the positive expression rate was 20%, 70%, 93% and 100%, Topo Ⅱ of positive expression rate was 10%, 60%, 73% and 90%, respectively. The comparison between groups and Topo Ⅱ expression levels in CIN and cervical cancer in previously untreated tissue difference was not statistically significant (P gt; 0.05), I among groups differences were statistically significant (P lt; 0.05). (2) of P-gp, GST-π, the relationship between the three of Topo Ⅱ: in cervical cancer resistance protein co-expression of P-gp and GST-π, P-gp and Topo Ⅱ expression showed significant positive correlation (P lt; 0.05); expression of GST-π and Topo Ⅱ was no significant correlation (P gt; 0.05). (3) P-gp, GST-π, Topo Ⅱ with previously untreated cervical cancer clinical and pathological features: P-gp, GST-π with newly diagnosed cervical cancer clinical stage, histological type and pathological grade ( , P gt; 0.05), of Topo Ⅱ with previously untreated cervical cancer clinical staging, histological grade (P gt; 0.05), histological type, adenocarcinoma was significantly lower than squamous cell carcinoma (P lt; 0.05) . (4) P-gp, GST-π, the relationship between Topo Ⅱ initial treatment of cervical cancer prognosis: P-gp, GST-π expression in 3-year survival rate was significantly lower than those with low expression difference was statistically significant ( P lt; 0.05); Topo II high expression and low expression of 3-year survival rates showed no statistical significance (P gt; 0.05). Univariate analysis showed that clinical stage, histological type, P-gp, GST-π with the prognosis of patients with cervical cancer, Multivariate analysis showed that clinical stage, histological type is an independent prognostic factors of cervical cancer patients. Conclusions: (1) P-gp, GST-π, Topo Ⅱ may be associated with the development of cervical cancer. (2) P-gp, GST-π high expression of the lower 3-year survival rate in patients with poor prognosis, suggesting that P-gp, GST-π can be used as indicators of cervical cancer prognosis. (3) cervical cancer tissue, the phenomenon of co-expression of multiple drug resistance gene, simultaneous detection of multiple drug resistance gene expression in cervical cancer chemotherapeutic drugs may have greater significance.
|